DR 30121
Alternative Names: DR-30121Latest Information Update: 23 Jun 2022
At a glance
- Originator Zhejiang Doer Biologics
- Class Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Age-related macular degeneration; Diabetic macular oedema
Most Recent Events
- 26 May 2022 Early research in Age-related macular degeneration in China (Parenteral) (Zhejiang Doer Biologics pipeline, May 2022)
- 26 May 2022 Early research in Diabetic macular oedema in China (Parenteral) (Zhejiang Doer Biologics pipeline, May 2022)
- 08 Dec 2021 Zhejiang Doer Biologics ain-licenses XS Technologies® from Lonza